Title Autocrine and / or paracrine growth of aggressive ATLL cells caused byHGF and c-Met

[1]  K. Takatsuki,et al.  Clinical and Hem atologic Features of 16 Cases , 2016 .

[2]  R. Hossein,et al.  of Adult T , 2012 .

[3]  R. Ueda,et al.  VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Aburatani,et al.  A genomic analysis of adult T-cell leukemia , 2007, Oncogene.

[5]  D. Bottaro,et al.  Targeting the c-Met signaling pathway in cancer. , 2008, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  Toshikazu Nakamura,et al.  Hepatocyte growth factor and the Met system as a mediator of tumor–stromal interactions , 2006, International journal of cancer.

[7]  P. Comoglio,et al.  Invasive growth: a MET-driven genetic programme for cancer and stem cells , 2006, Nature Reviews Cancer.

[8]  P. Comoglio,et al.  The Met pathway: master switch and drug target in cancer progression , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  I. Sekine,et al.  Interleukin-6- and tumour necrosis factor alpha-mediated expression of hepatocyte growth factor by stromal cells and its involvement in the growth of endometriosis. , 2005, Human reproduction.

[10]  M. Matsuoka,et al.  Natural history of adult T-cell leukemia/lymphoma and approaches to therapy , 2005, Oncogene.

[11]  B. Teicher,et al.  Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions , 2005 .

[12]  R. Haba,et al.  The tumour–stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients , 2004, British Journal of Cancer.

[13]  T. Waldmann,et al.  Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. , 2003, Cancer research.

[14]  K. Tobinai.  CHEMOTHERAPY OF ATL , 2003 .

[15]  M. Tomonaga,et al.  Expression of the c-Met proto-oncogene and its possible involvement in liver invasion in adult T-cell leukemia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  C. Tei,et al.  Autocrine and/or paracrine growth of adult T‐cell leukaemia tumour cells by interleukin 15 , 2002, British journal of haematology.

[17]  M. Tomonaga,et al.  Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. , 2002, Blood.

[18]  B. Zbar,et al.  Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. , 2002, The Journal of clinical investigation.

[19]  D. Saul,et al.  Autocrine antiapoptotic stimulation of cultured adult T-cell leukemia cells by overexpression of the chemokine I-309. , 2001, Blood.

[20]  K. Furge,et al.  Met receptor tyrosine kinase: enhanced signaling through adapter proteins , 2000, Oncogene.

[21]  G. Gaidano,et al.  The tyrosine kinase receptor Met and its ligand HGF are co-expressed and functionally active in HHV-8 positive primary effusion lymphoma , 2000, Leukemia.

[22]  M. Tomonaga,et al.  Interleukin-15 (IL-15) can replace the IL-2 signal in IL-2-dependent adult T-cell leukemia (ATL) cell lines: expression of IL-15 receptor alpha on ATL cells. , 1998, Blood.

[23]  G. Mufti,et al.  MANAGEMENT OF ADULT T‐CELL LEUKAEMIA/LYMPHOMA , 1998, British journal of haematology.

[24]  M. Tomonaga,et al.  Circulating interleukin‐6 levels are elevated in adult T‐cell leukaemia/lymphoma patients and correlate with adverse clinical features and survival , 1998, British journal of haematology.

[25]  K. Arimura,et al.  Alteration of cytokine levels by fosfomycin and prednisolone in spontaneous proliferation of cultured lymphocytes from patients with HTLV-I-associated myelopathy (HAM/TSP) , 1997, Journal of the Neurological Sciences.

[26]  K. Matsumoto,et al.  Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. , 1997, Cancer research.

[27]  M. Tomonaga,et al.  Frequent hepatic involvement in adult T cell leukemia: comparison with non-Hodgkin's lymphoma. , 1997, Leukemia & lymphoma.

[28]  A. Waage,et al.  Hepatocyte growth factor and its receptor c-met in multiple myeloma. , 1996, Blood.

[29]  M. Tomonaga,et al.  Features of the cytokines secreted by adult T cell leukemia (ATL) cells. , 1996, Leukemia & lymphoma.

[30]  W. Leonard,et al.  Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. , 1995, Science.

[31]  P. Boros,et al.  Hepatocyte growth factor: a multifunctional cytokine , 1995, The Lancet.

[32]  M. Shimoyama,et al.  Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphoma , 1991, British journal of haematology.

[33]  P. Comoglio,et al.  The receptor encoded by the human C‐MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors , 1991, International journal of cancer.

[34]  W. Blattner,et al.  Cytokine induction in HTLV‐I associated myelopathy and adult T‐cell leukemia: Alternate molecular mechanisms underlying retroviral pathogenesis , 1991, Journal of cellular biochemistry.

[35]  T. Waldmann,et al.  Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. , 1988, Blood.

[36]  John D. Minna,et al.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma , 1980, Proceedings of the National Academy of Sciences.